Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23013IDB-L5

Select Item

Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions.

Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants.

The Keratoconjunctivitis Sicca (Dry Eye) drugs in development market research report provide comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Keratoconjunctivitis Sicca (Dry Eye)
Key Targets
· Calcineurin; Glucocorticoid Receptor; Integrin Alpha L; Adiponectin Receptor Protein 1; Actin ; High Affinity Nerve Growth Factor Receptor; Transient Receptor Potential Cation Channel Subfamily M Member 8; Tumor Necrosis Factor; Nuclear Factor Kappa B; and N-Formyl Peptide Receptor 2
Key Mechanisms of Action
· Calcineurin Inhibitor; Glucocorticoid Receptor Agonist; Integrin Alpha L Antagonist; Adiponectin Receptor Protein 1 Agonist; Actin Inhibitor; High Affinity Nerve Growth Factor Receptor Agonist; Transient Receptor Potential Cation Channel Subfamily M Member 8 Activator; Tumor Necrosis Factor Inhibitor; Tyrosine Protein Kinase SYK Inhibitor; and N-Formyl Peptide Receptor 2 Agonist
Key Routes of Administration
· Ophthalmic; Oral; Topical; Nasal; Subcutaneous; Intravenous; Intraocular; Parenteral; Transdermal; and Sublingual
Key Molecule Types
· Small Molecule; Synthetic Peptide; Recombinant Protein; Peptide; Biologic; Cell Therapy; Monoclonal Antibody; Protein; Fusion Protein; and Blood Derivative
Major Companies
· Chongqing Kerun Biopharm R & D Co Ltd; Huons Co Ltd; Huons Global Co Ltd; IACTA Pharmaceuticals Inc; Jiangsu Hengrui Medicine Co Ltd; Ji Xing Pharmaceuticals Ltd; Jenivision Inc; IVIEW Therapeutics Inc; Ocular Therapeutix Inc; and Ocumension Therapeutics Co Ltd

Scope

  • Therapeutics in Development: Covering 175 molecules, with 172 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Keratoconjunctivitis Sicca (Dry Eye) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Keratoconjunctivitis Sicca (Dry Eye) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Keratoconjunctivitis Sicca (Dry Eye) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AB2 Bio Ltd
AbbVie Inc
Acahealth Pharma and Biotech Co Ltd
Actinobac Biomed Inc
Alchemedicine Co Ltd
Alcon Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
Allosterix Ltd
Allysta Pharmaceuticals Inc
Aramis Biosciences Inc
Ascendia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
Avixgen Inc
AxeroVision Inc
Azura Ophthalmics Pty Ltd
Bessor Pharma LLC
BRIM Biotechnology Inc
BSIM Therapeutics SA
Cambium Medical Technologies LLC
CAMP Therapeutics Inc
Cell2Cure Aps
Changchun Jinsai Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
China Medical System Holdings Ltd
Chong Kun Dang Pharmaceutical Corp.
Chongqing Kerun Biopharm R & D Co Ltd
Chromocell Corp
Cloudbreak Therapeutics LLC
Curexsys GmbH
Daewoo Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
EncuraGen Co Ltd
Eye Bio Korea Co Ltd
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
Grand Pharmaceutical Group Ltd
Grifols SA
H4Orphan Pharma
HanAll Biopharma Co Ltd
Hangzhou Yuansheng Biotechnology Co Ltd
Haplnscience Inc
Hbm Holdings Ltd
HLB Therapeutics Co Ltd
Huons Co Ltd
Huons Global Co Ltd
IACTA Pharmaceuticals Inc
Icure Pharmaceutical Inc
Ildong Pharmaceutical Co Ltd
IMD Farm Co Ltd
Incannex Healthcare Ltd
Inflamalps SA
Invirsa Inc
Invitrx Therapeutics Inc
Ipsen SA
IVIEW Therapeutics Inc
Japan Tobacco Inc
Jenivision Inc
Ji Xing Pharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Juvenescence UK Ltd
KALA BIO Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratorios Salvat SA
Link Biologics Ltd
LTT Bio-Pharma Co Ltd
MC2 Therapeutics AS
Medicon Pharmaceuticals Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
Neuroptika Inc
NicOx SA
NovaCell Technology Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis Holding AG
Ocumension Therapeutics Co Ltd
OKYO Pharma Ltd
Ophrx Ltd
Optus Pharmaceutical Co Ltd
Palatin Technologies Inc
Panag Pharma Inc
PharmaResearch Co Ltd
Pinotbio Inc
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Protokinetix Inc
Qilu Pharmaceutical Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
Regenerate Therapeutics Inc
RegeneRx Biopharmaceuticals Inc
ReGenTree LLC
Rhizen Pharmaceuticals SA
RHNanopharmacuticals LLC
RiniSight Inc
Rudacure Co Ltd
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
SCAI Therapeutics
Seinda Pharmaceutical Guangzhou Corp
Senelix Co Ltd
Senju Pharmaceutical Co Ltd
Serentrix LLC
SGN Nanopharma Inc
Shanghai Puyou Biomedical Co Ltd
SIFI Medtech Srl
SIFI SpA
Silk Technologies Ltd
Sinobioway Biomedical Co Ltd
Stuart Therapeutics Inc
Sunhawk Vision Biotech Inc
Surface Ophthalmics Inc
Surrozen Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TagCyx Biotechnologies
Tarsier Pharma Ltd
TearSolutions Inc
Telios Pharma Inc
TelomEye Pharmaceuticals Corp
Tetra Bio-Pharma Inc
The United Laboratories International Holdings Ltd
Theialife Sciences Pvt Ltd
Theratocular Biotek Co Ltd
Theratome Bio Inc
University of Waterloo
Vanda Pharmaceuticals Inc
Viatris Inc
Viva Vision Biotech
Wuhan Yicheng Biotechnology Co Ltd
Xequel Bio Inc
Xiamen University
Yuyu Pharma Inc
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Zhejiang Raytone Biotechnology Co Ltd
Zhuhai Essex Bio-Pharmaceutical Co Ltd
Zhuhai United Laboratories Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Keratoconjunctivitis Sicca (Dry Eye) reports
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 in real time.

  • Access a live Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more